Slide 1: Exchange disclosure cover letter
August 12, 2024 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai‐ 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: In ma on pur
Slide 2: Camlin Fine Sciences Limited Investor Presentation – August 2024
Camlin Fine Sciences Limited Investor Presentation – August 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Performance Highlights – Q1 FY25
Performance Highlights – Q1 FY 25 3
Slide 5: Q1FY25 Performance Highlights
Q1FY25 Performance Highlights Revenue (Rs. In Mn) EBITDA* (Rs. In Mn) PAT (Rs. In Mn) 4,196 4,017 3,959 447 120 284 -347 45 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 -818 Q1FY24 Q4FY24 Q1FY25 Key Highlights › Revenue stood at INR 395.85 crore which is slightly lower by 1.5% as compared to last quart
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. In Mn) Q1 FY25 Q1 FY24 YoY Q4 FY24 Q-O-Q FY24 Revenue from Operation 3,958.5 4,196.0 -5.7% 4,016.9 -1.5% 16,130.6 Raw material consumption 2,180.4 2,157.8 2,616.3 9,136.2 Employee Cost 511.8 438.5 461.7 1,787.5 Other expenses 1,085.0 1,212.6 1,07
Slide 7: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Particulars (Rs. In Mn) Q1 FY25 Q1 FY24 YoY Q4 FY24 Q-O-Q FY24 Revenue from Operation 1,819.1 1,611.1 12.9% 2,203.3 -17.4% 7,732.6 Raw material consumption 1,019.9 632.2 1,650.1 4,436.7 Employee Cost 168.1 154.8 165.4 659.5 Other expenses 561.7 573.2 644.2 2,365.2
Slide 8: Acquisition of Vitafor Invest NV
Acquisition of Vitafor Invest NV • Dresen Quimica SAPI De CV, Mexico has acquired 100% stake in Vitafor Invest Acquisition NV, Belgium and its underlying subsidiaries/associate on June 11, 2024 Details • 100% stake in Target Entity for Cash Consideration of € 1 (Euro One) Key Rationale Brief Backgro
Slide 9: Operational Revenue Breakup
Operational Revenue Breakup Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 979 1,017 978 2,153 3,132 2,860 1,843 2,587 1,608 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Performance Chemic
Slide 10: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 2,203 1,819 1,317 1,124 1,169 1,217 1,611 413 301 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn) 754 390 619 361 344 606 Q1FY24 Q4FY24 Q1FY25 Q
Slide 11: Company Overview – Q1 FY25
Company Overview - Q1 FY25 INGREDIENTS- Clg Ube
Slide 12: Company Overview
Company Overview FY24 Revenue Mix* ₹ 16,131 mn 26% 100+ 1,250+ Range of Diversified Base of Satisfied Products Customers Worldwide Preferred Partner High Quality & Wide 46% For Customized Shelf-Life Range Solutions Vanillin Manufacturer Among Global 61,000+ Specialty Ingredients Leaders Led by Integ
Slide 13: Global Footprint
Global Footprint 9 Capacity (MTPA) Global Manufacturing 31,000 Facilities Camlin Fine Sciences, India 5 Application Laboratories 6,000 CFS do Brasil 80+ CFS Europe SpA Italy CFS Wanglong Presence in China Countries 12,000 CFS Dresen, Mexico 2 R&D Centres 12,000 CFS Europe SpA, Italy Map not to scale
Slide 14: Product Highlights
Product Highlights FY24 Sales Mix% Key Products End User Industries Key Brands › TBHQ › Pet Food › Animal Feed Mills Straights 26% › BHA › Livestock Nutrition › Biodiesel › Ascorbyl palmitate (ASP) › Food & Beverages › Aquaculture & Fishmeal › Fish Meal › Rendering Specialty Ingredients › 200+ custo
Slide 15: Innovation at Work
Innovation at Work Process Optimization Initiatives • Vanillin Production Optimization: Continuous improvement at our new Dahej plant, refining processes and setting a future – oriented strategic direction • HQ Derivatives Process: Developed a novel, process with improved selectivity for producing H
Slide 16: Manufactured In-house
Integration Chain Phenol Hydroquinone Diphenols Catechol Manufactured In-house Performance Performance Specialty Ingredients Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Ethyl Vanillin
Slide 17: ESG
ESG • Main goal by 2030 is to switch to renewable electricity for all manufacturing facilities. Currently, company is exploring different options to achieve this goal Environment • Dedicated to sustainability and done few initiatives from reducing food waste to sourcing clean energy • Constantly see
Slide 18: Board of Directors
Board of Directors Name Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information Chairman & Managing Director systems, research & development, product development, and marketing › Holds a BA in Economics an
Slide 19: Senior Management Team
Senior Management Team Name › Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information Chairman & Managing Director systems, research & development, product development, and marketing › Holds a BA in Econom
Slide 20: Way Forward
Way Forward Specialty Ingredients Aroma Ingredients • Maintaining market leadership for • Introduce specialized and customized Antioxidants products within the vanillin range, catering to diverse application needs • Increasing focus on high margin blends and additives. These formulations are • Activ
Slide 21: Historical Financial Highlights
Historical Financial Highlights
Slide 22: Historical Financial Highlights
Historical Financial Highlights Margin Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 12.5% 15.3% 10.8% 12.7% 7.0% 2.8% 5.5% 4.3% 2.4% -6.5% 16,816 16,131 14,121 11,871 2,131 654 604 10,168 1,819 298 398 1,528 1,307 1,134 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 -1,049 FY20 FY21 FY2
Slide 23: Operational Revenue Break-Up
Operational Revenue Break-Up Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 11,400 9,679 4,576 7,288 4,111 7,980 3,812 5,103 6,171 2,860 4,168 5,516 2,381 3,135 3,311 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22
Slide 24: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 7,894 7,733 4,822 4,883 6,855 4,395 5,798 6,000 3,533 3,762 3,198 3,091 2,571 2,735 2,271 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 CFS Brazil (Rs. In Mn) CFS North America (Rs. I
Slide 25: Thank You !
Thank You ! Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – santosh.parab@camlinfs.com santosh.parab@camlinfs.com www.camlinfs.com www.camlinfs.com http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shri